This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Apogee Pharmaceuticals, Inc., Weihe Pharma{grave Over (c)}euticals Co. Ltd.. Active years: 2011-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 2 
1 out of 1 Years Active: 2011-2025
Title: Kaiji Hu: Innovator in Pharmaceutical Modulation
Introduction
Kaiji Hu is a notable inventor based in Burnaby, Canada. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of modulators and inhibitors that target specific enzymes. With a total of 3 patents to his name, Hu's work has the potential to impact various therapeutic areas.
Latest Patents
One of Hu's latest patents is focused on fatty acid amide hydrolase (FAAH) modulators, inhibitors, and their applications. This patent details compounds that can modulate or inhibit FAAH activity, which is crucial for various physiological processes. The pharmaceutical compositions derived from these modulators may offer new treatment avenues for conditions related to FAAH activity.
Another significant patent involves small molecules that act as monoacylglycerol lipase (MAGL) inhibitors. These compounds are designed to be used in pharmaceutical formulations aimed at treating a range of disorders, including anxiety, mood disorders, neurodegenerative diseases, and cancer. The versatility of these compounds highlights Hu's innovative approach to addressing complex health issues.
Career Highlights
Throughout his career, Kaiji Hu has worked with prominent companies in the pharmaceutical industry, including Apogee Pharmaceuticals, Inc. and Weihe Pharmaceuticals Co. Ltd. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.
Collaborations
Hu has collaborated with several professionals in his field, including Safwat Mohamed Rabea and Genhui Chen. These partnerships have likely contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Kaiji Hu's contributions to pharmaceutical innovation through his patents and collaborations demonstrate his commitment to advancing medical science. His work in developing FAAH and MAGL inhibitors showcases the potential for new therapeutic options in treating various health conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile